Cargando…
Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma
Previously, we conducted a randomized phase III trial of TPF (docetaxel, cisplatin, and 5-fluorouracil) induction chemotherapy in surgically managed locally advanced oral squamous cell carcinoma (OSCC) and found no improvement in overall survival. This study reports long-term follow-up results from...
Autores principales: | Zhong, Lai-ping, Zhang, Chen-ping, Ren, Guo-xin, Guo, Wei, William, William N., Hong, Christopher S., Sun, Jian, Zhu, Han-guang, Tu, Wen-yong, Li, Jiang, Cai, Yi-li, Yin, Qiu-ming, Wang, Li-zhen, Wang, Zhong-he, Hu, Yong-jie, Ji, Tong, Yang, Wen-jun, Ye, Wei-min, Li, Jun, He, Yue, Wang, Yan-an, Xu, Li-qun, Zhuang, Zhengping, Lee, J. Jack, Myers, Jeffrey N., Zhang, Zhi-yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621922/ https://www.ncbi.nlm.nih.gov/pubmed/26124084 |
Ejemplares similares
-
Long-Term Survival and Prognostic Factors in Locoregionally Advanced Nasopharyngeal Carcinoma Patients Treated with TPF Induction Chemotherapy followed by Cisplatin-Combined Concurrent Chemoradiotherapy
por: Zhang, Qun, et al.
Publicado: (2019) -
Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome
por: Ju, Wu‐tong, et al.
Publicado: (2021) -
Effect of CADM1 on TPF-induced chemotherapy in laryngeal squamous cell carcinoma
por: Nie, Jiani, et al.
Publicado: (2023) -
Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma
por: Chen, Ruijuan, et al.
Publicado: (2021) -
Two postoperative chemotherapies for gastric cancer: FOLFOX4 vs. TPF
por: Xie, Honghu, et al.
Publicado: (2019)